Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Trial Profile

Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs CERC 501 (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 11 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Nov 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top